AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32389679 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-month Sun Safe Schools intervention (N = 58)
Number of subjects: 118
Study 32389679 — intervention group
Group type: COMPARATOR
Intervention: Minimal informational control condition (N = 60)
Number of subjects: 118
Study 35762322 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 5988
Study 35762322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5988
Study 34639438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring Relaxation Program (HR)
Number of subjects: 30
Study 34639438 — intervention group
Group type: COMPARATOR
Intervention: Control group (Electrotherapy)
Number of subjects: 30
Study 35752793 — intervention group
Group type: EXPERIMENTAL
Intervention: New Chewing Problem Directory (CPD)
Number of subjects: 537
Study 33314079 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 431
Study 33314079 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 431
Study 33314079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 34748017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-formed OPRO® Gold Braces (MG2)
Number of subjects: 30
Study 34748017 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made laboratory constructed mouthguard (MG1)
Number of subjects: 30
Study 34748017 — intervention group
Group type: COMPARATOR
Intervention: Pre-fabricated Shock Doctor® Single Brace (MG3)
Number of subjects: 30
Study 34748017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 30
Study 33446083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 300
Study 33446083 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 32524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-optimized image without zoom
Number of subjects: 16
Study 32524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Reader-optimized measurement (ROM) images without zoom
Number of subjects: 16
Study 32524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-optimized image with zoom
Number of subjects: 16
Study 32524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Region of interest (ROI) with zoom
Number of subjects: 16
Study 32524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater agreement between readers
Number of subjects: 16
Study 35277166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine with 1 µg/kg dexmedetomidine in 20 ml for ESPB (Group E)
Number of subjects: 120
Study 35277166 — intervention group
Group type: COMPARATOR
Intervention: 0.375% ropivacaine for ESPB (Group C)
Number of subjects: 120
Study 34583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal oxygen, carbon dioxide, and mean arterial blood pressure (MAP) targets for 48 hours
Number of subjects: 120
Study 34583763 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal oxygen, carbon dioxide, and mean arterial blood pressure (MAP) targets for 48 hours
Number of subjects: 120
Study 34583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired CVR
Number of subjects: 120
Study 36165691 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Ross procedure
Number of subjects: 158
Study 36165691 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary Ross procedure
Number of subjects: 158
Study 33826709 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 or 300 mg
Number of subjects: 599
Study 36083489 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jieyu capsule
Number of subjects: 200
Study 36083489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34674843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous piperacillin/tazobactam for 24–48 h followed by 10 days of oral ciprofloxacin/metronidazole
Number of subjects: 39
Study 34674843 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 39
Study 34226192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaster cast
Number of subjects: 669
Study 34226192 — intervention group
Group type: COMPARATOR
Intervention: Removable brace
Number of subjects: 669
Study 35779616 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPR with PM and VOCs filter
Number of subjects: 40
Study 35779616 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPR with PM filter
Number of subjects: 40
Study 35779616 — intervention group
Group type: COMPARATOR
Intervention: Sham filter (no filtration)
Number of subjects: 40
Study 34161745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplement (0.11 mmol nitrate/kg as beetroot juice)
Number of subjects: 11
Study 34161745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 35377427 — intervention group
Group type: COMPARATOR
Intervention: Handgun carrying in the past 12 months
Number of subjects: 2002
Study 35377427 — intervention group
Group type: COMPARATOR
Intervention: Latent class growth analysis of handgun carrying trajectories
Number of subjects: 2002
Study 35377427 — intervention group
Group type: COMPARATOR
Intervention: Age at initiation of handgun carrying
Number of subjects: 2002
Study 35377427 — intervention group
Group type: COMPARATOR
Intervention: Frequency of carrying by age 26
Number of subjects: 2002
Study 34108160 — intervention group
Group type: EXPERIMENTAL
Intervention: Shonjibon Cash and Counselling (SCC) Trial combining nutrition counselling and unconditional cash transfer delivered on a mobile platform
Number of subjects: 2840
Study 34108160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition behaviour change communications (BCCs) and cash transfers
Number of subjects: 2840
Study 32056088 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR-LBBB patients with septal flash (LBBBTAVR+SF)
Number of subjects: 25
Study 32056088 — intervention group
Group type: COMPARATOR
Intervention: LBBBTAVR+SF
Number of subjects: 25
Study 32056088 — intervention group
Group type: COMPARATOR
Intervention: LBBBSF+PEF
Number of subjects: 25
Study 32056088 — intervention group
Group type: COMPARATOR
Intervention: LBBBSF+REF
Number of subjects: 25
Study 36418988 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile-enhanced Family Integrated Care (mFICare)
Number of subjects: 253
Study 36418988 — intervention group
Group type: COMPARATOR
Intervention: Family-Centered Care (FCC)
Number of subjects: 253
Study 36418988 — intervention group
Group type: EXPERIMENTAL
Intervention: mFICare (per-protocol analysis)
Number of subjects: 253
Study 32814310 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBA ergometer
Number of subjects: 6
Study 32814310 — intervention group
Group type: COMPARATOR
Intervention: Dansprint
Number of subjects: 6
Study 35751597 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal inattention symptoms
Number of subjects: 80
Study 35751597 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hyperactivity symptoms
Number of subjects: 80
Study 32842203 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor combined with ranitidine
Number of subjects: 70
Study 34592421 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal paced breathing (0.25 Hz)
Number of subjects: 30
Study 34592421 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow paced breathing (0.1 Hz)
Number of subjects: 30
Study 34592421 — intervention group
Group type: EXPERIMENTAL
Intervention: Su-soku practice
Number of subjects: 30
Study 36016996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 233
Study 36016996 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 233
Study 34581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (75 g)
Number of subjects: 74
Study 34581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (individually sweetness matched)
Number of subjects: 74
Study 34581796 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 74
Study 34581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose vs Sucrose
Number of subjects: 74
Study 34388414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg every 12 hours for up to 14 doses)
Number of subjects: 90
Study 34388414 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 90
Study 32220359 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-enriched fat modified diet
Number of subjects: 0
Study 32220359 — intervention group
Group type: COMPARATOR
Intervention: Control group (fat modified diet)
Number of subjects: 0
Study 35840996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 35840996 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing
Number of subjects: 0
Study 35840996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34518377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal bionic pancreas (BHBP)
Number of subjects: 10
Study 34518377 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 10
Study 35792253 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) on the tongue surface
Number of subjects: 24
Study 35653229 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8233 antisense oligonucleotide
Number of subjects: 73
Study 35653229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 32745878 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand weeding (no weedicide)
Number of subjects: 0
Study 32745878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emergence weedicide pendimethalin
Number of subjects: 0
Study 32745878 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-emergence weedicide imazethapyr for soybean
Number of subjects: 0
Study 32745878 — intervention group
Group type: EXPERIMENTAL
Intervention: Weedicide atrazine for maize
Number of subjects: 0
Study 32745878 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil depth
Number of subjects: 0
Study 32614422 — intervention group
Group type: EXPERIMENTAL
Intervention: AF episode duration of less than 24 hours
Number of subjects: 346
Study 32614422 — intervention group
Group type: COMPARATOR
Intervention: AF episode duration of longer than 24 hours
Number of subjects: 346
Study 37183246 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led arsenic mitigation program with point-of-use (POU) arsenic filters installed at baseline and followed for 2 years.
Number of subjects: 0
Study 34397680 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 80
Study 34397680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 32815803 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative opioid education
Number of subjects: 100
Study 32815803 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no preoperative opioid education)
Number of subjects: 100
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: < 5% weight loss group
Number of subjects: 180
Study 34915980 — intervention group
Group type: COMPARATOR
Intervention: WS/GG (weight-stable/gain)
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 10% weight loss group
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 5% weight loss
Number of subjects: 180
Study 34663391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 117
Study 34663391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 32799851 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-molecular-weight hyaluronic acid (HMW-HA) injection (Arthromac)
Number of subjects: 90
Study 32799851 — intervention group
Group type: COMPARATOR
Intervention: Triple low-molecular-weight hyaluronic acid (LMW-HA) injections (Hyalgan)
Number of subjects: 90
Study 36353351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup placement in true acetabulum
Number of subjects: 46
Study 36353351 — intervention group
Group type: COMPARATOR
Intervention: Cup placement in false acetabulum
Number of subjects: 46
Study 33048195 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic Haemostatic Assays (VHA)
Number of subjects: 396
Study 33048195 — intervention group
Group type: COMPARATOR
Intervention: Conventional Coagulation Tests (CCT)
Number of subjects: 396
Study 33048195 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic Haemostatic Assays (VHA) in TBI subgroup
Number of subjects: 396
Study 33048195 — intervention group
Group type: COMPARATOR
Intervention: Conventional Coagulation Tests (CCT) in TBI subgroup
Number of subjects: 396
Study 34767836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 18
Study 34555676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored axillary surgery (TAS)
Number of subjects: 296
Study 34555676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored axillary surgery (TAS) followed by axillary lymph node dissection (ALND)
Number of subjects: 296
Study 35366867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device app for inhaler education
Number of subjects: 90
Study 35366867 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer's instruction guide
Number of subjects: 90
Study 33558662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy + GM-CSF (Treatment group)
Number of subjects: 20
Study 33558662 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone (Control group)
Number of subjects: 20
Study 33417216 — intervention group
Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 24 weeks in MCI and PD, and 12 weeks in moderate and severe AD.
Number of subjects: 361
Study 33417216 — intervention group
Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 12 weeks in moderate and severe AD.
Number of subjects: 361
Study 33417216 — intervention group
Group type: COMPARATOR
Intervention: Orally administered plasmalogens (Pls) for 24 weeks in PD.
Number of subjects: 361
Study 36035829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent surgical hole towel
Number of subjects: 1220
Study 36035829 — intervention group
Group type: COMPARATOR
Intervention: Control group (disposable ophthalmic single-port operation cloth)
Number of subjects: 1220
Study 33184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game (See)
Number of subjects: 64
Study 33184023 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 64
Study 35855798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze pressure bandage with 2% chlorhexidine gluconate (Group A)
Number of subjects: 213
Study 35855798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile cotton swab with 2% chlorhexanol gluconate (Group B)
Number of subjects: 213
Study 35855798 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% alcohol sterile cotton swab wipe for basic needle maintenance (Group C)
Number of subjects: 213
Study 32580990 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered prednisolone 50 mg per day for up to 3 days, tapering to cessation over 10 days, in addition to guideline advice.
Number of subjects: 200
Study 32580990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32580990 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered prednisolone
Number of subjects: 200
Study 33231373 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (EVRYSDI®)
Number of subjects: 245
Study 35840905 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMRY EH101 dynamometer
Number of subjects: 1064
Study 35840905 — intervention group
Group type: COMPARATOR
Intervention: Jamar dynamometer
Number of subjects: 1064
Study 33853550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) at escalating doses starting from 6 Gy × 2 weekly fractions to a maximum of 6 Gy × 5 weekly fractions (dose level 4)
Number of subjects: 48
Study 33384335 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line infliximab (FL-IFX) - 5 mg/kg infusions at weeks 0, 2, 6, 14, and 22
Number of subjects: 100
Study 33384335 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment - exclusive enteral nutrition (EEN) or oral prednisolone (1 mg/kg, max 40 mg)
Number of subjects: 100
Study 33384335 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line infliximab (FL-IFX) on azathioprine monotherapy
Number of subjects: 100
Study 33384335 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment on azathioprine monotherapy
Number of subjects: 100
Study 33398094 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) with steroids
Number of subjects: 81
Study 33398094 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 81
Study 32473355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose followed by 90-mg twice daily maintenance for 1 year)
Number of subjects: 508
Study 32473355 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600-mg loading dose followed by 75-mg/d maintenance for 1 year)
Number of subjects: 508
Study 32473355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 508
Study 32473355 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 508
Study 33627763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (non-absorbable antibiotic) for 7 days
Number of subjects: 16
Study 33627763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 32961461 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education program
Number of subjects: 104
Study 32961461 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 104
Study 35229675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross motor skill-based exercise intervention (one weekly session for 25 weeks)
Number of subjects: 68
Study 35229675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 32342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg/day for 6 months
Number of subjects: 40
Study 32342619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33949268 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care interventions (specific interventions not detailed)
Number of subjects: 0
Study 36430041 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest stay
Number of subjects: 39
Study 36430041 — intervention group
Group type: COMPARATOR
Intervention: Field stay
Number of subjects: 39
Study 32950748 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg intravenous mirikizumab
Number of subjects: 84
Study 32950748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous mirikizumab
Number of subjects: 84
Study 32950748 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg subcutaneous mirikizumab (maintenance therapy)
Number of subjects: 84
Study 32950748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction phase)
Number of subjects: 84
Study 33257421 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of HbA1C
Number of subjects: 3560
Study 33257421 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of FPG
Number of subjects: 3560
Study 34973357 — intervention group
Group type: EXPERIMENTAL
Intervention: KT FIX Plus
Number of subjects: 0
Study 34973357 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 33047340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified, population management dashboard combined with practice facilitation
Number of subjects: 146826
Study 33047340 — intervention group
Group type: COMPARATOR
Intervention: Stepped-wedge controls
Number of subjects: 146826
Study 36055633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral occlusion of the uterine artery (LA)
Number of subjects: 58
Study 36055633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lateral occlusion)
Number of subjects: 58
Study 36055633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 33836310 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly PRT plus impact exercise training
Number of subjects: 172
Study 33836310 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising
Number of subjects: 172
Study 34878329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neurofeedback (NF) of an addiction-related brain region
Number of subjects: 54
Study 34878329 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback (NF)
Number of subjects: 54
Study 32898029 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on new guidelines for return to activity after concussion
Number of subjects: 21
Study 33431967 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% CO2 treatment
Number of subjects: 0
Study 33431967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CO2 concentration formulation
Number of subjects: 0
Study 33431967 — intervention group
Group type: COMPARATOR
Intervention: NaOH treatment (to correct medium acidification)
Number of subjects: 0
Study 33431967 — intervention group
Group type: COMPARATOR
Intervention: Knockdown of H+-sensing G protein-coupled receptor 65
Number of subjects: 0
Study 32500151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-grouped BMI-associated genetic instruments
Number of subjects: 634
Study 32500151 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly sampled sets of 100 or 200 BMI-associated genetic variants
Number of subjects: 634
Study 35090363 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg psilocybin
Number of subjects: 89
Study 35090363 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 89
Study 35090363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89